» Articles » PMID: 34180244

Lower In-Hospital Mortality With Beta-Blocker Use at Admission in Patients With Acute Decompensated Heart Failure

Abstract

Background It remains unclear whether beta-blocker use at hospital admission is associated with better in-hospital outcomes in patients with acute decompensated heart failure. Methods and Results We evaluated the factors independently associated with beta-blocker use at admission, and the effect of beta-blocker use at admission on in-hospital mortality in 3817 patients with acute decompensated heart failure enrolled in the Kyoto Congestive Heart Failure registry. There were 1512 patients (39.7%) receiving, and 2305 patients (60.3%) not receiving beta-blockers at admission for the index acute decompensated heart failure hospitalization. Factors independently associated with beta-blocker use at admission were previous heart failure hospitalization, history of myocardial infarction, atrial fibrillation, cardiomyopathy, and estimated glomerular filtration rate <30 mL/min per 1.73 m. Factors independently associated with no beta-blocker use were asthma, chronic obstructive pulmonary disease, lower body mass index, dementia, older age, and left ventricular ejection fraction <40%. Patients on beta-blockers had significantly lower in-hospital mortality rates (4.4% versus 7.6%, <0.001). Even after adjusting for confounders, beta-blocker use at admission remained significantly associated with lower in-hospital mortality risk (odds ratio, 0.41; 95% CI, 0.27-0.60, <0.001). Furthermore, beta-blocker use at admission was significantly associated with both lower cardiovascular mortality risk and lower noncardiovascular mortality risk. The association of beta-blocker use with lower in-hospital mortality risk was relatively more prominent in patients receiving high dose beta-blockers. The magnitude of the effect of beta-blocker use was greater in patients with previous heart failure hospitalization than in patients without ( for interaction 0.04). Conclusions Beta-blocker use at admission was associated with lower in-hospital mortality in patients with acute decompensated heart failure. Registration URL: https://www.upload.umin.ac.jp/; Unique identifier: UMIN000015238.

Citing Articles

Beta-blocker administration within 24 hours after admission to the intensive care unit and mortality in critical heart failure patients: a retrospective analysis from the MIMIC-IV database.

Xie L, Chen J, Li Y, Liu G, Shen J, Li X Front Pharmacol. 2025; 16:1514138.

PMID: 40078276 PMC: 11897012. DOI: 10.3389/fphar.2025.1514138.


Safety and efficacy of early beta-blocker initiation in acute heart failure and cardiogenic shock: systematic review and meta-analysis.

Sinardja C, Jagannatha G, de Liyis B, Kosasih A Egypt Heart J. 2024; 76(1):126.

PMID: 39271587 PMC: 11399533. DOI: 10.1186/s43044-024-00558-3.


Cardiogenic pulmonary edema - is it lone cardiogenic? "Missing link" between hemodynamic and other existing mechanisms.

Sisakian H, Tavaratsyan A Am J Cardiovasc Dis. 2024; 14(2):81-89.

PMID: 38764545 PMC: 11101961. DOI: 10.62347/YGQQ8696.


Beta Blockers Improve Prognosis When Used Early in Patients with Cardiogenic Shock: An Analysis of the FRENSHOCK Multicenter Prospective Registry.

Cardelli L, Cherbi M, Huet F, Schurtz G, Bonnefoy-Cudraz E, Gerbaud E Pharmaceuticals (Basel). 2023; 16(12).

PMID: 38139866 PMC: 10747751. DOI: 10.3390/ph16121740.


Beta-blocker use and mortality among patients with systolic heart failure and pacemaker rhythm.

Perry A, Maggioni A, Tavazzi L, Levy W ESC Heart Fail. 2023; 10(3):1972-1979.

PMID: 36999245 PMC: 10192283. DOI: 10.1002/ehf2.14353.


References
1.
Tsutsui H, Momomura S, Masuyama T, Saito Y, Komuro I, Murohara T . Tolerability, Efficacy, and Safety of Bisoprolol vs. Carvedilol in Japanese Patients With Heart Failure and Reduced Ejection Fraction - The CIBIS-J Trial. Circ J. 2019; 83(6):1269-1277. DOI: 10.1253/circj.CJ-18-1199. View

2.
Tan K, Harazim M, Tang B, McLean A, Nalos M . Correction to: The association between premorbid beta blocker exposure and mortality in sepsis-a systematic review. Crit Care. 2020; 24(1):3. PMC: 6942344. DOI: 10.1186/s13054-019-2699-8. View

3.
Prins K, Neill J, Tyler J, Eckman P, Duval S . Effects of Beta-Blocker Withdrawal in Acute Decompensated Heart Failure: A Systematic Review and Meta-Analysis. JACC Heart Fail. 2015; 3(8):647-53. PMC: 4777602. DOI: 10.1016/j.jchf.2015.03.008. View

4.
Ponikowski P, Voors A, Anker S, Bueno H, Cleland J, Coats A . 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special.... Eur Heart J. 2016; 37(27):2129-2200. DOI: 10.1093/eurheartj/ehw128. View

5.
Yamamoto E, Kato T, Ozasa N, Yaku H, Inuzuka Y, Tamaki Y . Kyoto Congestive Heart Failure (KCHF) study: rationale and design. ESC Heart Fail. 2017; 4(3):216-223. PMC: 5542729. DOI: 10.1002/ehf2.12138. View